Adam Steensberg, Zealand Pharma CEO
Following lukewarm launch and layoffs, Zealand Pharma is licensing out its diabetes drug to Novo Nordisk
In March, Zealand Pharma gutted its US workforce and said it was looking for strategic partnerships for its diabetes products following a disappointing first year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.